(Reuters) — Getinge (PINK:GETI B) last week reported its biggest quarterly order intake increase for almost 2 years, saying costs to resolve U.S. regulatory problems would be lower than previously expected. The firm has seen its profit margins eroded in recent years by slower sales growth, price pressure and quality control problems in the U.S. Order intake was 7.4 […]
Getinge
Getinge unveils major overhaul
Getinge (STO:GETI-B) said today that it’s planning a major overhaul that will see its 3 divisions merged into 1 by the beginning of next year, as it targets organic sales growth of 2% to 4% over the next few years. The Swedish medical device giant said it expects the moves to generate annual EBITA gains […]
Maquet recalls Flow-i anesthesia systems
Maquet Cardiovascular, Getinge‘s (PINK:GETI B) medical subsidiary, is recalling its Flow-i anesthesia systems according to an FDA posting. The company began notifying customers of the product recall on April 2. The FDA labeled the recall a Class I, the most serious type of recall issued by the federal watchdog, indicating that “there is a reasonable […]
FDA panel on aneurysm devices | Regulatory news for the week of April 27, 2015
Maquet’s TigerPaw II recall is Class I
Getinge shares jump on FDA deal
Maquet inks marketing deals with ClearFlow, InterValve
Getinge trims sales forecast as Q3 falls short
Maquet recalls intra-aortic balloon pumps on shutdown risk
Biomet puts itself back on public market | Medtech Wall Street news for the week of Mar. 10, 2014
Biomet announces IPO plans
March 7, 2014 by Brad Perriello
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
Siemens, GE named among worst-performing device makers of the year | MassDevice.com On Call
MASSDEVICE ON CALL — Medtech giants have seen Wall Street bumps so far this year, but several of the company’s in the industry’s top 40 haven’t been so fortunate.